HAE
Haemonetics Corporation
HAE's fundamentals are mixed, but it looks expensive: trading at 54x earnings, above its usual 42x.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HAE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Under pressure |
HAE's cash flow is currently strong, and its revenue and profitability are stable, but its balance sheet is under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HAE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 25x | $56.99 | -54% |
| Fair | 41x | $93.28 | -24% |
| Current | 54x | $123 | — |
| Expensive | 66x | $150 | +22% |
Historical ranges are pointers, not guarantees.
HAE's PE is in its expensive range at 54x.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HAE Forward outlook
There aren't enough analyst estimates for HAE to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HAE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $2.26 | -34% |
| Q2 2026 | $2.07 | -37% |
| Q1 2026 | $2.05 | -38% |
| Q4 2025 | $3.63 | +43% |
| Q3 2025 | $3.42 | +42% |
| Q2 2025 | $3.27 | +47% |
| Q1 2025 | $3.31 | +45% |
| Q4 2024 | $2.54 | +2.8% |
HAE has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
HAE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $357.8M | +9.3% |
| Q2 2026 | $339.4M | +5.6% |
| Q1 2026 | $346.4M | +4.8% |
| Q4 2025 | $339M | -2.7% |
| Q3 2025 | $327.3M | -5.3% |
| Q2 2025 | $321.4M | -4.4% |
| Q1 2025 | $330.6M | -3.7% |
| Q4 2024 | $348.5M | +3.7% |
HAE's revenue has picked up after two years of holding roughly level: $358M last quarter, up 9.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +3.1 points |
| Q2 2026 | 17% | +0.2 points |
| Q1 2026 | -6.7% | -28 points |
| Q4 2025 | 20% | +2.9 points |
| Q3 2025 | 18% | +2.9 points |
| Q2 2025 | 17% | +4.9 points |
| Q1 2025 | 22% | +13 points |
| Q4 2024 | 17% | +3.3 points |
HAE has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over HAE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
HAE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $113.3M | +6.6% |
| Q2 2026 | $44.4M | +226% |
| Q1 2026 | $53.3M | -47% |
| Q4 2025 | $87.2M | +148% |
| Q3 2025 | $106.3M | +170% |
| Q2 2025 | $13.6M | +$46.7M |
| Q1 2025 | $100.9M | +86% |
| Q4 2024 | $35.2M | +$58.1M |
HAE generated $298M in free cash flow over the past year, up 16% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
HAE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +759K shares |
| 1 year | -2.5% | -1.2M shares |
| 3 years | -9.6% | -4.9M shares |
| 5 years | -9.7% | -5M shares |
| Available history | -10% | -5.2M shares |
HAE has 46M diluted shares, down 2.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | $100M |
| Q4 2025 | — |
| Q1 2025 | $150M |
| Q4 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HAE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HAE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 2.4x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 2.7x | Moderate |
| Q4 2024 | 3.1x | Elevated |
HAE's net debt is about 3.0 years of its operating earnings (EBITDA), up from 2.6 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HAE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 78.5 | Overbought |
| Stochastic | 82.3 | Overbought |
HAE's weekly RSI is 79 (overbought) and its Stochastic is 82 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HAE PE vs Healthcare Sector
| Metric | HAE | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 26x | 110% above |
| PE % | 67 | 29 | 38 pts above |
HAE is trading at 54x earnings, a 110% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HAE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $116.0 | 5.8% above |
| 20 week MA | $101.3 | 21% above |
| 50 week MA | $80.9 | 52% above |
| 100 week MA | $72.9 | 68% above |
| 200 week MA | $78.4 | 57% above |
HAE has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
HAE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $115.9 | $118.8 | +2.4% |
| 2021 | $118.8 | $54.2 | -54% |
| 2022 | $54.2 | $79.2 | +46% |
| 2023 | $79.2 | $85.5 | +8% |
| 2024 | $85.5 | $77.6 | -9.3% |
| 2025 | $77.6 | $80.3 | +3.5% |
| 2026 YTD | $80.3 | $122.7 | +53% |
HAE has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.